The EDITION 4 trial was a 6 mo, multicenter, randomized, open-label, parallel-group study comparing the efficacy and safety of Glar-300 and Glar-100 [randomized (1 : 1 : 1 : 1) to once-daily Glar-300 or Glar-100], injected in the morning or evening, while continuing mealtime insulin in patients with T1DM, with a 6 mo safety extension period. This evidence concerns the gene INS and type 1 diabetes mellitus.